Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Canadian Cancer Trials Group MDC.1 (S1117) - A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)) - was permanently closed to accrual on November 15, 2014.

The trial had been on a temporary hold to accrual since April 15, 2014 with the expectation that the study would reopen as a phase III trial. Based on the phase II results, the lead group's DSMC recommended the primary treatment comparison results be reported and the study not proceed to phase III. Patients are being notified of these findings.

The study did very well in Canada enrolling 34 patients in less than 1 year.

Thanks to all centres, staff and patients for participating in this trial.

Canadian Cancer Trials Group CEC.2 (NCCTG 0577) - A Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p and 19q Codeleted Anaplastic Glioma) - was closed to accrual and patient follow-up as of today at 5pm.

Accrual to this study has been on hold since May 27, 2013. The lead group has amended the trial extensively and has re-opened accrual in the US. The Canadian Cancer Trials Group has decided to re-open the amended study as a new trial -- Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma) -- will be centrally activated as CEC.6.

Thank you to everyone who worked on this trial.